Sign in
GTHX Stock Price, Chart, Stats & News
G1 Therapeutics, Inc.
Save
G1 Therapeutics, Inc. (GTHX) does not currently pay a dividend.
377.75M
Market cap
–
Current P/E
–
Forward P/E
GTHX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 91.28% |
Operating margin | -47.91% |
Pretax margin | -54.36% |
Net margin | -58.13% |
Effective tax rate | -6.95% |
ROA | -39.47% |
ROE | -92.13% |
D/E | 1.62x |
Interest coverage ratio | -3.94x |
GTHX valuation
P/E | – |
P/S | 4.58x |
P/B | 10.47x |
P/CF | -9.66x |
P/FCF | -9.85x |
P/OCF | -9.66x |
PEG | -0.08x |
EV multiple | -10.29x |
About
G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds.
Similar securities
Based on sector and market capitalization
Report issue